The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s kidney cancer drugs market report forecasts the kidney cancer drugs market size to grow to $9.33 Billion by 2027, with a CAGR (compound annual growth rate) of more than 4%.

Learn More On The Kidney Cancer Drugs Market Report 2023 – https://www.thebusinessresearchcompany.com/report/kidney-cancer-drugs-global-market-report

Kidney Cancer Drugs Market Size Forecast
The global kidney cancer drugs market is expected to grow from $7.41 billion in 2022 to $7.81 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global kidney cancer drugs market size is expected to grow to $9.33 billion in 2027 at a CAGR of 4.5%.

North America held the largest kidney cancer drugs market share, and Middle East was the fastest-growing region in 2022.

Key Kidney Cancer Drugs Market Driver ­– Rise In The Incidence Of Renal Cancer
For instance, in January 2022, according to the American Cancer Society, a US-based health organization that works for cancer elimination, there will be 79,000 new instances of kidney cancer diagnosed (50,290 men and 28,710 women), and 13,920 people will pass away from the disease (8,960 men and 4,960 women). The majority of people are diagnosed between the ages of 65 and 74, with an average diagnosis age of 64. When a person is under the age of 45, kidney cancer is quite rare. thus driving the growth of the kidney cancer drug market.

Request for A Sample Of The Global Kidney Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2591&type=smp

Key Kidney Cancer Drugs Market Trend – Adopting Combination Therapy
Combination therapy combines the effects of various drugs, thereby reducing the likelihood of cancer-resistant cells developing. The improved understanding of renal cancer causes and effects has led to the discovery of combination therapy. Under this treatment, the drugs from vascular endothelial growth factor (VEGF), which stimulate the protein in the blood, are combined with inhibitors of the mammalian target of rapamycin (mTOR), which helps promote cellular biogenesis. For instance, in November 2021, Merck & Co., Inc., a US-based research-oriented biopharmaceutical company, announced that the anti-PD-1 drug KEYTRUDA from Merck has received FDA approval for the adjuvant treatment of renal cell carcinoma (RCC) patients who are at intermediate-high or high risk of recurrence after nephrectomy or after nephrectomy with resection of metastatic lesions.

Kidney Cancer Drugs Market Segment
1) By Type: Renal Cell Carcinoma, Urothelial Carcinoma, Others (Renal Sarcoma, Renal Lymphoma)
2) By Product: Nexavar (Sorafenib), Sutent (Sunitinib), Afinitor (Everolimus), Votrient (Pazopanib), Avastin (Bevacizumab), Inlyta (Axitinib), Torisel (Temsirolimus), Proleukin (Aldesleukin), Other Products
3) By End Users: Hospitals, Clinics, Research Center, Other End-Users

Kidney Cancer Drugs Market Major Players and Strategies
Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc., Novartis International AG, Exelixis Inc., F. Hoffmann-La Roche Ag, Genentech Inc., Glaxosmithkline PLC., Active Biotech, Amgen, Thermo Fisher Scientific Inc., Bristol-Myers Squibb, Eisai, Roche, Cipla Limited, Onyx, Abbott Laboratories, Aveo Pharmaceuticals, Immatics Biotechnologies, Prometheus Laboratories, Argos Therapeutics, Myriad Genetics Inc., NeoGenomics Laboratories, NanoString Technologies Inc., Sysmex Corporation, Rosetta Genomics, Illumina Inc. and Quest Diagnostics Incorporated.

In October 2022, LG Chem, Ltd., a South Korea-based chemical company, acquired AVEO Oncology for $566 million. The acquisition gives LG Chem’s Life Sciences Division a commercial footprint in the United States, diversifies its pipeline with a wide range of oncology treatments, and speeds up LG Chem’s efforts to deliver ongoing growth. Both companies anticipate establishing a global oncology organisation with a strong portfolio of cutting-edge products supported by full capabilities from discovery to clinical, biologics manufacturing, and U.S. commercialization, at a scale capable of broadening access to treatment options. AVEO Oncology is a US-based, commercial-stage, oncology-focused biopharmaceutical company dedicated to providing cancer patients with drugs that improve their quality of life.

The Kidney Cancer Drugs Global Market Report 2023 covers regional data on kidney cancer drugs market size, kidney cancer drugs market trends and drivers, opportunities, strategies, and kidney cancer drugs market competitor analysis. The countries covered in the kidney cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Kidney cancer drugs that can treat kidney cancer. Because they can reach cancer cells practically anywhere in the body, these treatments are known as systemic therapy. Several different types of medications may be used, depending on the type of kidney cancer. It functions by stopping tyrosine kinases, which are crucial proteins in cancer cells that aid in growth and survival, or angiogenesis, the development of new blood vessels that feed malignancies.

View More Reports Related To The Kidney Cancer Drugs Market –
Lung Cancer Drugs Global Market Report 2023
Skin Cancer Drugs Global Market Report 2023
Pancreatic Cancer Drugs Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: